Pneumolysin Attenuates Lethal Streptococcus pneumoniae Superinfection Following SARS-CoV-2 Infection
Austin W Todd1, Ekaterina Koroleva1, Danielle B Molotsky1
1Department of Microbiology, Immunology, and Molecular Genetics, University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, TX 78229, USA.
Abstract:
Streptococcus pneumoniae (Spn) is a common bacterial co-infection in patients with respiratory viral infections, including influenza and SARS-CoV-2, and is associated with increased morbidity and mortality. However, the mechanisms underlying the severe disease caused by SARS-CoV-2 and Spn co-infection remain poorly understood. Here, we show that Spn infection 3 days after infection with mouse-adapted SARS-CoV-2 MA10 markedly increased morbidity and mortality in wild-type mice. In contrast, SARS-CoV-2 infection 3 days after Spn infection did not increase mortality, demonstrating that disease severity depends on the sequence of infection. Increased susceptibility to Spn following SARS-CoV-2 infection was associated with enhanced viral burden, exacerbated lung pathology, pronounced neutrophil accumulation, and increased expression of IFN-β and the neutrophil-recruiting chemokine CXCL2. To determine whether pneumolysin (PLY), a major Spn virulence factor, contributes to superinfection-induced pathology, we infected mice with a PLY-deficient Spn strain. Unexpectedly, PLY deficiency further increased mortality and lung pathology without altering bacterial or viral titers. Immunofluorescence analysis revealed increased accumulation of neutrophils and macrophages in the lungs of mice co-infected with PLY-deficient Spn. These results indicate that Spn superinfection exacerbates SARS-CoV-2-induced lung disease, whereas PLY unexpectedly attenuates disease severity. We propose that PLY limits immunopathology during SARS-CoV-2-Spn superinfection by restraining macrophage- and neutrophil-mediated inflammation.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
06:06Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
Published on: September 11, 2020
Related Concept Videos
Pneumonia II: Pathophysiology
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
